晚期胃癌转化治疗后手术切除的临床疗效观察

Q4 Medicine

肿瘤研究与临床 Pub Date : 2019-11-28 DOI:10.3760/CMA.J.ISSN.1006-9801.2019.11.008

Kai Jia, Liwei Wang, Junjie Ma, Jinfeng Ma, Jun Xu

{"title":"晚期胃癌转化治疗后手术切除的临床疗效观察","authors":"Kai Jia, Liwei Wang, Junjie Ma, Jinfeng Ma, Jun Xu","doi":"10.3760/CMA.J.ISSN.1006-9801.2019.11.008","DOIUrl":null,"url":null,"abstract":"Objective \nTo observe the clinical effect of surgical resection after conversion therapy for patients with advanced gastric cancer. \n \n \nMethods \nThe clinical data of 23 patients with advanced gastric cancer who were admitted to Shanxi Provincial Cancer Hospital from January 2015 to October 2017 were retrospectively analyzed. All patients underwent multi-disciplinary treatment(MDT)-directed conversion therapy, and D2 radical gastrectomy was performed after the disappearance of non-healing factors. The remission of patients after conversion therapy and the related intraoperative and postoperative indicators were analyzed. \n \n \nResults \nAfter the conversion therapy, there were 2 cases (8.7%) of complete remission, 13 cases (56.5%) of partial remission and 8 cases (34.8%) of stable disease. The remission rate of the conversion therapy was 65.2% (15/23). In all 23 cases, the surgical time was (135.5±32.1) min, the intraoperative blood loss was (356.7±101.3) ml, the number of lymph nodes resected was 35.5±10.3. The time of gastric tube indwelling was (70.5±29.6) h, the time to first liquid intake was (85.0±21.5) h, the time of drainage tube placement was (196.2±36.2) h and the postoperative hospital stay was (10.7±3.2) d. After surgery, two cases had grade ⅢA post-operative complications and 2 had gradeⅡ. All patients were followed up, the median progression-free survival time was 13.5 months and the median overall survival time was 21.9 months. \n \n \nConclusion \nThe survival time of patients with advanced gastric cancer can be prolonged by D2 radical gastrectomy after the MDT-guided conversion therapy. \n \n \nKey words: \nGastric neoplasms; Surgical procedures, operative; Conversion therapy; Multi-disciplinary team","PeriodicalId":9505,"journal":{"name":"肿瘤研究与临床","volume":"31 1","pages":"756-759"},"PeriodicalIF":0.0000,"publicationDate":"2019-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Clinical efficacy of surgical resection after conversion therapy for advanced gastric cancer\",\"authors\":\"Kai Jia, Liwei Wang, Junjie Ma, Jinfeng Ma, Jun Xu\",\"doi\":\"10.3760/CMA.J.ISSN.1006-9801.2019.11.008\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objective \\nTo observe the clinical effect of surgical resection after conversion therapy for patients with advanced gastric cancer. \\n \\n \\nMethods \\nThe clinical data of 23 patients with advanced gastric cancer who were admitted to Shanxi Provincial Cancer Hospital from January 2015 to October 2017 were retrospectively analyzed. All patients underwent multi-disciplinary treatment(MDT)-directed conversion therapy, and D2 radical gastrectomy was performed after the disappearance of non-healing factors. The remission of patients after conversion therapy and the related intraoperative and postoperative indicators were analyzed. \\n \\n \\nResults \\nAfter the conversion therapy, there were 2 cases (8.7%) of complete remission, 13 cases (56.5%) of partial remission and 8 cases (34.8%) of stable disease. The remission rate of the conversion therapy was 65.2% (15/23). In all 23 cases, the surgical time was (135.5±32.1) min, the intraoperative blood loss was (356.7±101.3) ml, the number of lymph nodes resected was 35.5±10.3. The time of gastric tube indwelling was (70.5±29.6) h, the time to first liquid intake was (85.0±21.5) h, the time of drainage tube placement was (196.2±36.2) h and the postoperative hospital stay was (10.7±3.2) d. After surgery, two cases had grade ⅢA post-operative complications and 2 had gradeⅡ. All patients were followed up, the median progression-free survival time was 13.5 months and the median overall survival time was 21.9 months. \\n \\n \\nConclusion \\nThe survival time of patients with advanced gastric cancer can be prolonged by D2 radical gastrectomy after the MDT-guided conversion therapy. \\n \\n \\nKey words: \\nGastric neoplasms; Surgical procedures, operative; Conversion therapy; Multi-disciplinary team\",\"PeriodicalId\":9505,\"journal\":{\"name\":\"肿瘤研究与临床\",\"volume\":\"31 1\",\"pages\":\"756-759\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-11-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"肿瘤研究与临床\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3760/CMA.J.ISSN.1006-9801.2019.11.008\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"肿瘤研究与临床","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1006-9801.2019.11.008","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

目的观察中晚期癌症患者转流治疗后手术切除的临床效果。方法回顾性分析山西省癌症医院2015年1月至2017年10月收治的23例晚期癌症患者的临床资料。所有患者均接受了多学科治疗（MDT）指导的转化治疗，在不愈合因素消失后进行D2根治性胃切除术。分析转化治疗后患者病情的缓解情况及术中、术后相关指标。结果转治后病情完全缓解2例（8.7%），部分缓解13例（56.5%），病情稳定8例（34.8%）。转化治疗的缓解率为65.2%（15/23）。23例患者手术时间为（135.5±32.1）min，术中出血量为（356.7±101.3）ml，切除淋巴结数为35.5±10.3。留置胃导管时间为（70.5±29.6）h，首次取液时间为（85.0±21.5）h，放置引流管时间为（196.2±36.2）h，术后住院时间为（10.7±3.2）d。对所有患者进行随访，中位无进展生存时间为13.5个月，中位总生存时间为21.9个月。结论D2根治性胃切除术可延长晚期癌症患者的生存时间。关键词：胃肿瘤；外科手术；转化疗法；多学科团队

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Clinical efficacy of surgical resection after conversion therapy for advanced gastric cancer

Objective To observe the clinical effect of surgical resection after conversion therapy for patients with advanced gastric cancer. Methods The clinical data of 23 patients with advanced gastric cancer who were admitted to Shanxi Provincial Cancer Hospital from January 2015 to October 2017 were retrospectively analyzed. All patients underwent multi-disciplinary treatment(MDT)-directed conversion therapy, and D2 radical gastrectomy was performed after the disappearance of non-healing factors. The remission of patients after conversion therapy and the related intraoperative and postoperative indicators were analyzed. Results After the conversion therapy, there were 2 cases (8.7%) of complete remission, 13 cases (56.5%) of partial remission and 8 cases (34.8%) of stable disease. The remission rate of the conversion therapy was 65.2% (15/23). In all 23 cases, the surgical time was (135.5±32.1) min, the intraoperative blood loss was (356.7±101.3) ml, the number of lymph nodes resected was 35.5±10.3. The time of gastric tube indwelling was (70.5±29.6) h, the time to first liquid intake was (85.0±21.5) h, the time of drainage tube placement was (196.2±36.2) h and the postoperative hospital stay was (10.7±3.2) d. After surgery, two cases had grade ⅢA post-operative complications and 2 had gradeⅡ. All patients were followed up, the median progression-free survival time was 13.5 months and the median overall survival time was 21.9 months. Conclusion The survival time of patients with advanced gastric cancer can be prolonged by D2 radical gastrectomy after the MDT-guided conversion therapy. Key words: Gastric neoplasms; Surgical procedures, operative; Conversion therapy; Multi-disciplinary team

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

肿瘤研究与临床 Medicine-Oncology

CiteScore

0.10

自引率

0.00%

发文量

7737

期刊介绍： "Cancer Research and Clinic" is a series of magazines of the Chinese Medical Association under the supervision of the National Health Commission and sponsored by the Chinese Medical Association. It mainly reflects scientific research results and academic trends in the field of malignant tumors. The main columns include monographs, guidelines and consensus, standards and norms, treatises, short treatises, survey reports, reviews, clinical pathology (case) discussions, case reports, etc. The readers are middle- and senior-level medical staff engaged in basic research and clinical work on malignant tumors.